Assessing NH300094, a novel dopamine and serotonin receptor modulator with cognitive enhancement property for treating schizophrenia.

ABSTRACT: Background: Schizophrenia is a serious psychiatric disorder that significantly affects the quality of life of patients. The objective of this study is to discover a novel antipsychotic candidate with highly antagonistic activity against both serotonin and dopamine receptors, demonstrating robust efficacy in animal models of positive, negative, and cognitive symptoms of schizophrenia. Methods: In the present study, we examined the activity of antipsychotic drug (NH300094) on 5-HT_2A, 5-HT_2C, 5-HT_1A, 5-HT_1B, 5-HT₇, H₁, M₁, Alpha_1A, D_2L, D_2S, Alpha_2A, D₃ receptor functional assay in vitro. In addition, multiple animal models, including dizocil

SUBMITTER: Feng Z 

PROVIDER: S-EPMC10848157 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature